Science
Adolescent and young adult (AYA) patients need additional support while they experience the challenges associated with their age. They need specific training to learn the knowledge and skills required to confidently self-manage their allergies and/or asthma. Transitional care is a complex process which should address the psychological, medical, educational and vocational needs of AYA in the developmentally appropriate way. The European Academy of Allergy and Clinical Immunology has developed a clinical practice guideline to provide evidence-based recommendations for healthcare professionals to support the transitional care of AYA with allergy and/or asthma. This guideline was developed by a multi-disciplinary working panel of experts and patient representatives based on two recent systematic reviews. It sets out a series of general recommendations on operating a clinical service for AYA, which include: (i) starting transition early (11-13 years), (ii) using a structured, multidisciplinary approach, (iii) ensuring AYA fully understand their condition and have resources they can access, (iv) active monitoring of adherence and (v) discussing any implications for further education and work. Specific allergy and asthma transition recommendations include (i) simplifying medication regimes and using reminders; (ii) focusing on areas where AYA are not confident and involving peers in training AYA patients; (iii) identifying and managing psychological and socioeconomic issues impacting disease control and quality of life; (iv) enrolling the family in assisting AYA to undertake self-management and (v) encouraging AYA to let their friends know about their allergies and asthma. These recommendations may need to be adapted to fit into national healthcare systems.
Access the guideline here
Access the guideline here
Overview of Guideline by Graham Roberts
The Survey by Kate Khaleva
Challenges by Audrey DunnGalvin
Interventions by Recebba Knibb
PPI Survey by Claudia Gore
The Guidelines by Marta Vazquez-Ortiz
Primary Care by Liz Angier
Patients by Hazel Gowland
Tribute to Claude Molina
Claude Molina was born in Algiers in 1924. The early loss of his brother , 7 years younger, at the age of 17, affected him deeply, as did his parents’ demise and the early stages of a war in Algeria. He nevertheless completed brilliant studies and was appointed Pneumo-physiology professor as early as 1958, which was also the year of his marriage. He used to say: “All along my life, my wife’s love and the bond that kept us united kept me going”. Nelly Molina produced two sons who were his pride. Today, Jean-Michel Molina is at the head of the infectious disease ward of the Saint Louis hospital in Paris. He made his mark through his research on HIV. As to Thierry Molina, he is equally at the head of the anatomic pathology ward of the Necker hospital in Paris. Claude lavished his affection on his four grandchildren: David, Gabrielle, Mathieu and Noah.
In 1962, Algeria becoming independent, he left the country and was offered the pneumology chair at the Clermont Ferrand CHRU. He was soon recognized internationally as an expert in the field of pneumology and allergology through his research on inflammation in asthma and through his co-discovery (with Jack Pepys) of the farmer’s lung disease.
As president of the European academy of allergology and clinical immunology, from 1983 to 1986, he created the Post-graduate courses as well as the editorial and audio-visual committee. In 2013, he was awarded the EAACI D. Bovet prize for his action advocating and promoting allergology. Professor Emeritus, he retired in 1992 but did not cease to work.
As correspondent of the National Academy of Medicine, he strongly advocated and supported the creation of allergology as a specialty, while keeping his clinical acumen and pedagogical interests. He believed that the teaching of allergology had to be case-based and rooted in practical experience, as explained in his book , « L’Allergologie à l’aube du 3ème millénaire » (Allergology at the dawn of the 3rd millenium), which is a remarkable synthesis of current knowledge, from fundamental sciences to day to day medical applications. In 2001, Claude Molina and Franz Marrache develop an on-line continuing medical education programme which will lead to the “Bibliography Update Abstracts” (BUA) published monthly by EAACI, which he will keep working on, until his demise.
Claude Molina died at the age of 95 on Thursday 27th, February 2020. We would like to express our admiration for his enthusiasm, for the relevance of his stand, for his action, for his youth that we deemed eternal. In our memory, he will remain delightful, intellectually curious and eager to let his students give their best. He belongs to the humanistic tradition and will be missed.
We would like to express our sympathy to his wife, his children, his whole family. Let our admiration, our friendship, our affection for Claude help soothe their sorrow. A beautiful human being, Claude will forever remain alive in our memory.
JG
EAACI recognizes excellence in basic and clinical research in the field of allergy and clinical immunology and awards the title of EAACI Fellow to EAACI members who have excelled in their field. EAACI fellows will form an elite advisory board that will be called upon by the Academy on various matters in future years.
EAACI Fellows are selected each year on the basis of previous research record (h-index) and outstanding contributions to the field of allergy and clinical immunology.
Requirements:
1) Be an active EAACI member (mandatory)
2) Currently or previously active in EAACI committees, interest groups, sections, guidelines and/or task forces (mandatory)
3) Qualifications*:
a. Score: Scopus h-factor >45 and/or research gate score >45 with 98% based on publications**
b. Leading in large research consortia, i.e. ERC
c. First or senior author in breakthrough papers
d. Leading in clinical guidelines
*At least 2 out of 4 qualifications should apply
**Younger members <45 years can qualify with lower h-factor when qualification b and/or c applies
For any queries please contact: EAACIfellows@eaaci.org
-
EAACI Fellows 2019
 |
Cezmi Akdis Dr. Cezmi Akdis has been awarded the FEAACI in 2019 for his continuous excellence in the field and major discoveries on mechanisms of immune tolerance to allergens, mechanisms of eczema, human Treg cells, human Breg cells, human ILCreg cells, role of histamine receptor 2 in immune tolerance, first papers on antigen-specific T cell plasticity. |
|
 |
Gennaro d'Amato |
|
 |
Barry Kay Dr. Barry Kay has been awarded the FEAACI in 2019 for his continuous excellence in the field and major discoveries related to the role of eosinophils and T cells in allergy and asthma. |
|
 |
Torsten Zuberbier Dr. Torsten Zuberbier has been awarded the FEAACI in 2019 for his continuous excellence in the field and major discoveries related to the role of mast cells in allergy, and the establishment of long-term cult model of human skin mast cells. |
|
Task Force Regulations
EAACI Task Forces
Task forces are scientific activities that deal with specific topics that are relevant, controversial, or new in the field. All EAACI members can apply for a specific task force in alignment with the chair and secretary of a specific section, interest group or working group. In addition, Task Forces can be assembled by the Executive Committee in case a strategic direction is to be prioritized or following the proposal of the Research and Outreach Committee or the Science Committee.
Structure
a. Task Forces have a Chair and a Secretary, responsible for application process, reporting and evaluation, budget usage and publication of the task force outcomes
b. A core group of maximum of 12 members is responsible for the coordination of the activities, together with the Chair and the Secretary. The core group is mentioned in the application process. Additional members can be added as needed and should be mentioned in the description of the TF.
c. All core group members applying Task Force members must be EAACI members in good standing
d. EAACI encourages the joint involvement of different Sections, Interest groups or Working groups in the development of a Task Force
e. In case of joint TF with external scientific groups or involvement of members with leadership positions in other societies or structures the existence of MoUs should be checked, together with the conflict of loyalty and an NDA should be provided by the external participants
Application and selection process
a. Application for new Task Forces must be completed via the EAACI budget platform by September of each year for the next year
b. All Task Forces are evaluated by the Scientific Committee, Research and Outreach Committee or the Methodology Committee (depending on the topic) and approved by the EAACI Executive Committee
c. Task Forces have the average duration of 2 years, and can be extended to a longer period if proof of activity is provided; the extension needs ExCom approval
d. Applications for EAACI Task Forces must follow the budget rules in EAACI bylaws Art.8
e. All members of the Task Forces are required to provide a declaration of interest and check the rules for the conflict of loyalty during the process of Task Force application
Task Force Outcomes
1. Timely budget application
2. Regular activity reports: one per year to the ExCom in relation to the budget application, every 6 months to the Scientific Committee, Research and Outreach Committee or the Methodology Committee (depending on the topic)
3. Scientific output (see separate description)
4. Short summary for the website and social media
5. Lay summary for the patients’ website
Publication policies
a. All publications (guidelines, consensus documents, reports, position papers, decision charts, videos, etc.) must be approved evaluated by the Scientific Committee, Research and Outreach Committee or the Methodology Committee (depending on the topic) and submitted for approval to the EAACI Executive Committee
b. Task Forces are not allowed to use EAACI’s name on publications that have not been approved by the EAACI Executive Committee
c. All publications should be done, unless otherwise approved by the Executive Committee, in EAACI journals, the EAACI Media Library, the EAACI website and/or other EAACI platforms
d. All publications should clearly state the financial support of EAACI
e. Coverage of the article processing charge for manuscript publication, art graphics, translations, or other publication related expenses by EAACI should be discussed in the Science Committee and with the EAACI Treasurer
EAACI Media Library
The EAACI Media Library gives you access to hundreds of scientific items to view on-demand from wherever you are in the world.
|
|
|
|
|
|
|
-
Highlights
Guidelines
 |
 |
 |
 |
-
Books
Log-in and enjoy at your leisure
 |
 |
 *Also available in Greek, Spanish and Chinese |
 *Also available in Greek, Portuguese and Spanish |
 |
 |
This platform serves the central EAACI goals of promoting research, disseminating scientific information to encourage continuous education and functioning as a scientific reference body for professionals and organisations involved in allergy, asthma and clinical immunology.
First time access: please provide an email, login information and confirm you have read the T&C's and disclaimer.
Returning users: simply enter your email and away you go!
We hope you enjoy learning from experts and outstanding researchers in our field who kindly share their work, views and findings on the library.
Any feedback regarding the EAACI Media Library is welcome: communications@eaaci.org
Returning users: simply enter your email and away you go!
We hope you enjoy learning from experts and outstanding researchers in our field who kindly share their work, views and findings on the library.
Any feedback regarding the EAACI Media Library is welcome: communications@eaaci.org
Find all EAACI books and guidelines on the EAACI Media Library
Are you an EAACI Member? Access all Journals' content for free-
Log in here
-
Allergy 
Publisher
Allergy Journal is an official EAACI journal published by Wiley-Blackwell
Impact Factor
Allergy ranks 1st in Allergy with an IF of 14.710
The Team
Led by Prof. Cezmi Akdis (Editor-in-Chief) and Maria Jose Torres (Deputy Editor)
Pediatric Allergy and Clinical Immunology
Publisher
PAI Journal is an official EAACI journal published by Wiley-Blackwell
Impact Factor
PAI ranks 10th in Allergy with an IF of 5.464
The Team
Led by Prof. Philippe Eigenmann (Editor-in-Chief) and Doris Kollman (Managing Editor)Clinical and Translational Allergy
Publisher
CTA is an official EAACI journal published by Wiley-Blackwell
Impact Factor
CTA ranks 12th in Allergy with an IF of 5.657
The Team
Led by Prof. Jean Bousquet (Editor-in-Chief) and Dr. Clive Grattan (Editor-in-Chief)
Please note that EAACI is not resposible for the content of these websites
Allergome: A Database of Allergenic Molecules
AllFam
BioMedSearch
ExPASy Molecular Biology Server
Global Initiative for Asthma
February recommended reads
Sign up for receiving the updates by email here
Electronic cigarette (e-cigarette) and asthma
P.W Clapp et al JACI 2020 145 97 9
The e-cigarette has definitely acquired the right place in the arsenal of smoking cessation. Its development is accompanied by a notable drop in smoking in spite, in France, price increases. To tell the truth “vaping” persists more than one year after smoking cessation. This is to say it is necessary to pay attention to inhalation risks, as mentioned by the French National Academy, already in 2015 and more recently ( G. Dubois: Bulletin de l’ANM 2019 in press Commission V).
In USA, vaping is responsible in 2019 of 2409 hospitalizations particularly in young asthmatics, whereas usually this sensitive population is little inclined to smoking. Among the multiple substances, probably involved and detected in bronco-alveolar lavages the diacetyl, vitamin E oil and foam cells (however nonspecific, V.Guerini Lancet Feb 2020), were identified. Nevertheless, e-cigarette attracts adolescents (5 million in USA). It must be monitored and regulated, with a ban in promotion and to minors, given the frequency of chronic pulmonary diseases, such asthma with risks of exacerbations, status asthmaticus, and life threatening.
Epitopes of major peanut allergen Ara h 2 and promising hypoallergen for immunotherapy
Tscheppe et al JACI 2020 145 229-238
In 48 patients with peanut allergy, the sera tested with IgE-binding and basophil activation assays showed that both types of epitopes contributed to allergic reactions to Ara h 2 in a patient-specific manner.
A set of Ara h 2 derivatives with removed linear and/or conformational epitopes was produced after reduction and alkylation leading to an Ara h2 mutant.
The hypo-allergens so produced showed abolished IgE binding and highly reduced basophil activation but retained their ability to activate allergen-specific T cells.
This hypo-allergen did not induce anaphylactic reactions in a mouse model of peanut allergy.
The observation that both types of IgE epitopes had to be removed to produce an efficacious hypo-allergen should inform immunotherapy trials. Future animal studies will assess further safety and effectiveness to help direct these trials in allergic patients.
Nemolizumab (N): Hope confirmed in moderate or severe atopic dermatitis with pruritus
J.I.Silverberg et al JACI 2020145 1 173-182
In a preliminary study published in 2018 by the Japanese authors N had shown efficacy in the treatment of Atopic Dermatitis (AD) More recently an Euro-American group took over this study which now concerns 226 patients compared with placebo (55) by this monoclonal antibody which blocks alpha subunit of IL 31 receptor, a key pathway of skin lesions and pruritus.
In a randomized double blind trial phase 2 B lasting 24 weeks with subcutaneous injection every 4 weeks, 3 dosages were compared: 10mg, 30mg and 90mg. All doses reduced AD severity but the best effectiveness was observed with the 30mg dose, as judged with 4 scores among them Eczema Area and severity index and Physician’s global assessment.
One third 33% achieved clear skin by week 16 versus 12% in placebo group. Itch was rapidly reduced at the 1st week with maximum at week 16, (69% versus 35% placebo) with an acceptable safety profile (few episodes of pharyngitis and respiratory involvement). N deserves a major place among all biotherapies of AD.
Sexual hormones and asthma
Y-Y Han et al AJRCCM 2020 201 2 15 January
The role of hormones may explain sex differences in asthma. The team of Pittsburg sought to examine sex hormone levels of free testosterone and estradiol and asthma in adults by cross-sectional study in 7,615 adults (3,953 men and 3,662 women) aged 18-79 years who participated in the 2013-2014 and 2015-2016 U.S. NHN Survey. Logistic regression was conducted separately in women and men.
Results: Free testosterone levels in the fourth quartile were associated with lower odds of current asthma in women. Given an interaction between obesity and sex hormones on current asthma, these results were stratified by obesity. In this analysis, elevated free testosterone and estradiol levels were associated with reduced odds of current asthma in obese women, and an elevated serum estradiol was associated with lower odds of current asthma in nonobese men.
Conclusions: These findings confirm that sex hormones play a role in known sex differences in adult asthma, suggest that obesity modifies their effects but must be interpreted with caution.
-
Paraphenylene-diamine, hair dye, hair dresser and skin damage without a contact allergy
Meisser, Sanne S. et al. JACI Volume 145, Issue 2, 619 - 631.e2
Phenylenediamine (PPD) is a strong contact allergen used in hair dye that is known to cause allergic contact dermatitis (ACD). Both private and occupational exposure to PPD is frequent, but the effect of PPD exposure in nonallergic occupationally exposed subjects is unknown.
Results :
RNA sequencing demonstrated downregulation of tight junction and stratum corneum proteins in the skin of patients with severe ACD after PPD exposure. Claudin-1 (CLDN-1), CLDN8, CLDN11, CXADR-like membrane protein (CLMP), occludin (OCLN), membrane-associated guanylate kinase inverted 1 (MAGI1), and MAGI2 mRNA expression was downregulated in patients with severe ACD. CLDN1 and CLMP expression were downregulated in nonresponding hairdressers and patients with mild ACD. Filaggrin 1 (FLG1), FLG2, and loricrin (LOR) expression were downregulated in patients with ACD. Conclusion: PPD-exposed skin is associated with extensive changes, including downregulation of tight junction and stratum corneum proteins, even in the absence of clinical symptoms.
Your comments and questions are welcome at the following addresses:
Claude Molina - claude.nelly.molina@orange.fr
Jacques Gayraud - gayraud65@wanadoo.fr
*register to receive the bibliographic updates via email
Find all EAACI position papers and consensus documents on the EAACI Media Library
2018
-
Issue 53Volume 4, 2018 -
Issue 52Volume 3, 2018 -
Issue 51Volume 2, 2018 -
2017
2016
2015
2014
2013
2012
-
Issue 29November 2012 -
Issue 28August 2012 -
Issue 27May 2012 -
Issue 26January 2012
2011
-
Issue 25September 2011 -
Issue 24May 2011 -
Issue 23January 2011
2010
-
Issue 22September 2010 -
Issue 21May 2010 -
Issue 20February 2010
2009
-
Issue 19October 2009 -
Issue 18May 2009 -
Issue 17January 2009
2008
-
Issue 16September 2008 -
Issue 15May 2008 -
Issue 14January 2008
2007
-
Issue 13September 2007 -
Issue 12June 2007 -
Issue 11February 2007
2006
-
Issue 10October 2006 -
Issue 9May 2006 -
Issue 8March 2006
2005
-
Issue 7November 2005 -
Issue 6June 2005